ClinicalTrials.Veeva

Menu

Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression

C

Chongqing Medical University

Status

Completed

Conditions

Major Depressive Disorder
Psychiatric Disorder
Metabolic Disorder

Treatments

Diagnostic Test: 17-HAMD

Study type

Observational

Funder types

Other

Identifiers

NCT06331572
1stChongqingMU-TRD

Details and patient eligibility

About

This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.

Enrollment

162 patients

Sex

All

Ages

12 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

FEDN-MDD:

  1. Age 12-18 years
  2. Meet the diagnostic criteria for MDD according to the DSM-5
  3. First-episode and drug-naive
  4. HAMD-17 score > 17

TRD:

  1. Age 12-18 years
  2. Meet the diagnostic criteria for MDD according to the DSM-5
  3. HAMD-17 score > 13
  4. Currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms <50%)

HC:

  1. age 12-18 years
  2. HAMD-17 score < 7
  3. HCs without a personal history of a mental illness or family history in a first-degree relative

Exclusion criteria

FEDN-MDD、TRD:

  1. the presence or past history of severe medical, neurological or psychiatric disorders (other than MDD in patients)
  2. anxiety comorbidity was not considered an exclusion criterion provided that MDD was the main diagnosis and the primary reason for seeking assistance
  3. substance abuse, head trauma, or loss of consciousness
  4. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
  5. Pregnant and lactating women

HC:

  1. the presence or past history of severe medical, neurological or psychiatric disorders
  2. substance abuse, head trauma, or loss of consciousness
  3. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
  4. Pregnant and lactating women

Trial design

162 participants in 3 patient groups

TRD
Description:
1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 3. HAMD-17 score \> 13 4. currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%)
Treatment:
Diagnostic Test: 17-HAMD
FEDN-MDD
Description:
1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 2. First-episode and drug-naive 4. HAMD-17 score \> 17
Treatment:
Diagnostic Test: 17-HAMD
HC
Description:
1. age 12-18 years 2. HAMD-17 score \< 7 3. HCs without a personal history of a mental illness or family history in a first-degree relative
Treatment:
Diagnostic Test: 17-HAMD

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems